The Phase 2 trial reference point The Phase 2 retatrutide trial (Jastreboff et al., New England Journal of Medicine 2023) enrolled 338 adults across placebo and retatrutide arms at 1, 4, 8, and 12 mg weekly
At this time, we believe the timing parameters for invitation issuance and the proposed 65-day response window are appropriate to support valid, comparable measurement across facilities while balancing operational feasibility
Dosage Equivalents Across Different Products When changing Vitamin B12 products, knowing the dosage is key
For an 8 mg dose, draw 1.6 mL
IV access, pump rate control, and emergency response capacity are typical reasons IV NAD+ is administered in licensed clinic settings rather than home research-use settings
We adjust the dose based on how well theyre doing and lab results